Related Experiment Video
Updated: Jan 3, 2026
08:01
A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
Published on: August 12, 2016
9.4K
Non-nutritive Sweeteners and Glycaemic Control.
Yoona Kim1, Jennifer B Keogh2, Peter M Clifton3
1Department of Food and Nutrition, College of Natural Science, Gyeongsang National University, Jinju, Republic of Korea.
Current Atherosclerosis Reports
|November 20, 2019
Summary
Non-nutritive sweeteners (NNS) show no clear effect on type 2 diabetes or glycaemic control. Long-term studies are needed to confirm the impact of NNS consumption on metabolic health.
Area of Science:
- Nutrition Science
- Metabolic Health
- Endocrinology
Background:
- Global consumption of non-nutritive sweeteners (NNS) has risen significantly over 30 years.
- Consumers often choose NNS for potential weight management benefits over sugar.
Purpose of the Study:
- To review the effects of NNS consumption on glycaemic control.
- To investigate the impact of NNS on type 2 diabetes incidence.
Main Methods:
- Analysis of epidemiological studies.
- Review of human intervention trials.
- Examination of animal studies.
Main Results:
- Current evidence does not clearly link NNS consumption to type 2 diabetes incidence or altered glycaemic control.
- Potential mechanisms include NNS interaction with sweet taste receptors and gut hormone secretion (GLP-1, PYY, ghrelin, GIP).
- Evidence suggests NNS may modify the gut microbiome.
Conclusions:
- Firm conclusions on NNS's role in glycaemic control require further long-term research.
- The precise impact of NNS on metabolic health remains uncertain.
- Further investigation into NNS-gut-brain axis interactions is warranted.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
487
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
487
01:06Oral Hypoglycemic Agents: Glinides
538
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
538
01:17Oral Hypoglycemic Agents: Sulfonylureas
685
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
685
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
543
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
543
01:24Glucagon-like Receptor Agonists
790
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
790
01:15Hypoglycemia and Glucagon
750
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
750